Literature DB >> 8822205

Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor.

A Sawano1, T Takahashi, S Yamaguchi, M Aonuma, M Shibuya.   

Abstract

Placenta Growth Factor (PIGF) is a new member of vascular endothelial growth factor (VEGF) family. Although VEGF binds Flt family Flt-1 and KDR/Flk-1 tyrosine kinases at high affinity for signal transduction, biological activities and the receptors of PIGF have not been extensively studied. Reverse transcription-PCR showed that PIGF-2, a subtype of PIGF-1 that bears a basic amino acid-rich domain, is more abundant than PIGF-1 and thus is the major subtype in human placenta. Using antibodies specific to PIGF-1 or -2 as markers, we obtained large amounts of PIGFs in the baculovirus expression system. PIGF-2 had growth-stimulatory activity on human umbilical vein endothelial cells and vascular permeability activity in the Miles assay at levels about 10-fold lower than those of VEGF. All PIGF-1 activities were lower than those of PIGF-2. Both PIGFs competed for the binding of 125I-labeled VEGF to Flt-1 receptor but not to KDR/Flk-1 expressed on NIH3T3 cells. Furthermore, 125I-labeled PIGF bound to Flt-1 at high affinity but not to KDR/Flk-1. Supporting the notion that PIGF can use only Flt-1 as a receptor, PIGF activated Flt-1 to autophosphorylate, whereas PIGF could not generate signals from KDR/Flk-1. These results indicate that Flt-1, but not KDR/Flk-1, is a receptor for PIGF, suggesting that the weak biological activities of PIGF are due to its use of only part of the available VEGF signaling. These mild characteristics of PIGF may be important for the appropriate development and maintenance of normal placental tissue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822205

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  67 in total

1.  Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch.

Authors:  M Félétou; J Staczek; J Duhault
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Differential mitogenic responses of human macrovascular and microvascular endothelial cells to cytokines underline their phenotypic heterogeneity.

Authors:  I Lang; C Hoffmann; H Olip; M A Pabst; T Hahn; G Dohr; G Desoye
Journal:  Cell Prolif       Date:  2001-06       Impact factor: 6.831

Review 3.  Overcoming resistance to antiangiogenic therapies.

Authors:  Sabine Tejpar; Hans Prenen; Massimiliano Mazzone
Journal:  Oncologist       Date:  2012-07-06

4.  Association between genetic variations of vascular endothelial growth factor receptor 2 and glioma in the Chinese Han population.

Authors:  Hongyan Chen; Weimin Wang; Zhao Xingjie; Xiao Song; Weiwei Fan; Zhou Keke; Gong Chen; Yao Zhao; Ying Mao; Daru Lu
Journal:  J Mol Neurosci       Date:  2012-01-25       Impact factor: 3.444

5.  Eyes wide s-flt: clearly, avascular fidelity is a vascular endothelial growth factor family affair.

Authors:  Royce Mohan
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

6.  Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1.

Authors:  Ori Nevo; Nima Soleymanlou; Yuan Wu; Jing Xu; John Kingdom; Ariel Many; Stacy Zamudio; Isabella Caniggia
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-04-20       Impact factor: 3.619

7.  Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy.

Authors:  Jenny Yao; Xiumin Wu; Guanglei Zhuang; Ian M Kasman; Tobias Vogt; Vernon Phan; Masabumi Shibuya; Napoleone Ferrara; Carlos Bais
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

8.  Excess vascular endothelial growth factor-A disrupts pericyte recruitment during blood vessel formation.

Authors:  Jordan Darden; Laura Beth Payne; Huaning Zhao; John C Chappell
Journal:  Angiogenesis       Date:  2018-09-20       Impact factor: 9.596

Review 9.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

10.  Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Authors:  John V Ilekis; Ekaterini Tsilou; Susan Fisher; Vikki M Abrahams; Michael J Soares; James C Cross; Stacy Zamudio; Nicholas P Illsley; Leslie Myatt; Christine Colvis; Maged M Costantine; David M Haas; Yoel Sadovsky; Carl Weiner; Erik Rytting; Gene Bidwell
Journal:  Am J Obstet Gynecol       Date:  2016-03-10       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.